AJİNKYA GUPTE, PRASAD RAJ DANDEKAR, ROHAN KADAM, MAYANK DHOUNDIYAL, NASEEM ALAND SHAIKH, AMOL KAKADE, RANJEET BAJPAI, VİJAY HARIBHAKTI
Turkish Journal of Oncology - 2025;40(1):1-10
OBJECTIVE This study explores ultra-hypofractionated breast radiation therapy in 110 Stage I-III breast cancer patients, focusing on dosimetry, toxicity, overall survival (OS), and disease-free survival (DFS). METHODS Conducted from May 2020 to May 2023, the study enrolled patients undergoing ultra-hypofractionated adjuvant radiation therapy post-surgery. Dosimetric parameters were recorded, and toxicity was assessed using SPSS software. Patients underwent either Modified Radical Mastectomy (MRM) or Breast Conservation Surgery (BCS), receiving 26 Gy in 5 fractions over 1 week or a simultaneous integrated boost (SIB) of 6 Gy after BCS. Deep Inspiratory Breath Hold and Surface Guided Radiation Therapy were employed. RESULTS The study enrolled 110 patients. Toxicity at the end of treatment included 89% Grade 1 skin toxicity and 18.18% Grade 1 dysphagia, with minimal Grade 2 skin toxicity at the last follow-up. Dosimetric analysis confirmed adequate coverage within organs-at-risk constraints. The 2-year OS was 95.6%, and DFS was 92.7%. CONCLUSION The study shows that ultra-hypofractionated breast radiation therapy is feasible and effective, achieving a favorable overall survival of 95.6%. Dosimetric constraints were met with good acceptance. The retrospective nature and absence of a control group present limitations, urging further exploration.
